Zoetis (MIL:1ZTS) Cyclically Adjusted Revenue per Share: €15.59 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1ZTS Zoetis Inc MIL:1ZTS
55 GF Score
Price €65.52
GF Value €167.22
Valuation Significantly Undervalued
View Full Analysis

What is Zoetis Cyclically Adjusted Revenue per Share?

Zoetis MIL:1ZTS -0.85% 55 Cyclically Adjusted Revenue per Share is €15.59 as of Mar. 2026. GuruFocus rates MIL:1ZTS with a GF Score™ of 55/100 and a GF Value™ of €167.22 (Significantly Undervalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zoetis's adjusted revenue per share for the three months ended in Mar. 2026 was €4.632. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €15.59 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Zoetis's average Cyclically Adjusted Revenue Growth Rate was 8.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Zoetis was 10.40% per year. The lowest was 7.90% per year. And the median was 9.00% per year.

As of today (2026-07-23), Zoetis's current stock price is €65.52. Zoetis's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €15.59. Zoetis's Cyclically Adjusted PS Ratio of today is 4.20.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zoetis was 19.62. The lowest was 4.07. And the median was 11.64.


Zoetis  (MIL:1ZTS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zoetis's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=65.52/15.59
=4.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zoetis was 19.62. The lowest was 4.07. And the median was 11.64.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zoetis Cyclically Adjusted Revenue per Share Related Terms


Zoetis Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zoetis's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zoetis Cyclically Adjusted Revenue per Share Chart

Zoetis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 13.88 15.79 15.13

Zoetis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.39 14.68 14.80 15.13 15.59

MIL:1ZTS vs UTHR, VTRS, NBIX: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zoetis Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zoetis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zoetis's Cyclically Adjusted PS Ratio falls into.


MIL:1ZTS
55GF Score
Zoetis Inc MIL:1ZTS
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zoetis Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zoetis's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.632/330.2130*330.2130
=4.632

Current CPI (Mar. 2026) = 330.2130.

Zoetis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 2.155 241.018 2.953
201609 2.221 241.428 3.038
201612 2.438 241.432 3.335
201703 2.324 243.801 3.148
201706 2.286 244.955 3.082
201709 2.295 246.819 3.070
201712 2.513 246.524 3.366
201803 2.262 249.554 2.993
201806 2.485 251.989 3.256
201809 2.611 252.439 3.415
201812 2.838 251.233 3.730
201903 2.665 254.202 3.462
201906 2.839 256.143 3.660
201909 2.987 256.759 3.842
201912 3.137 256.974 4.031
202003 2.898 258.115 3.707
202006 2.875 257.797 3.683
202009 3.169 260.280 4.020
202012 3.102 260.474 3.933
202103 3.289 264.877 4.100
202106 3.390 271.696 4.120
202109 3.551 274.310 4.275
202112 3.660 278.802 4.335
202203 3.804 287.504 4.369
202206 4.117 296.311 4.588
202209 4.310 296.808 4.795
202212 4.126 296.797 4.591
202303 4.021 301.836 4.399
202306 4.347 305.109 4.705
202309 4.368 307.789 4.686
202312 4.411 306.746 4.748
202403 4.391 312.332 4.642
202406 4.810 314.175 5.056
202409 4.744 315.301 4.968
202412 4.905 315.605 5.132
202503 4.538 319.799 4.686
202506 4.787 322.561 4.901
202509 4.614 324.800 4.691
202512 4.648 324.054 4.736
202603 4.632 330.213 4.632

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €15.59 mean?
Zoetis (MIL:1ZTS) has a Cyclically Adjusted Revenue per Share of €15.59 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zoetis and its competitors.
Is Zoetis' Cyclically Adjusted Revenue per Share too high?
Zoetis' current Cyclically Adjusted Revenue per Share is €15.59. Overall, Zoetis has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' Cyclically Adjusted Revenue per Share compare to UTHR and VTRS?
Zoetis' Cyclically Adjusted Revenue per Share of €15.59 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zoetis and its competitors. Zoetis's current Cyclically Adjusted Revenue per Share is €15.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (MIL:1ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is €167.22, compared to a current price of €65.52 — trading 60.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €15.59. Zoetis' overall GF Score™ is 55/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zoetis (MIL:1ZTS), the current Cyclically Adjusted Revenue per Share is €15.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zoetis (MIL:1ZTS) Overvalued in 2026?

Based on GuruFocus' analysis, Zoetis stock appears to be undervalued. The current stock price of €65.52 is trading 60.8% below its estimated GF Value™ of €167.22. GuruFocus considers Zoetis to be Significantly Undervalued.

Key valuation signals for MIL:1ZTS:

  • Cyclically Adjusted Revenue per Share: €15.59
  • GF Value™: €167.22 vs. price of €65.52 (60.8% below fair value)
  • GF Score™: 55/100

No single metric tells the full story. See the MIL:1ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zoetis Business Description

Address 10 Sylvan Way, Parsippany, NJ, USA, 07054
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
55GF Score

Get the complete analysis for MIL:1ZTS

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.52
Price
€167.22
GF Value